Date: 26 October 2023 Your Name: __MAU ERN POH_____ Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known): _____ TLCR-23-691_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
з	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have no conflict of interest

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: 26 October 2023 Your Name: Chee Shee Chai Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):______TLCR-23-691______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have no conflict of interest for this manuscript. Thank you.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: 26 October 2023 Your Name:_CHONG KIN LIAM_____ Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):______TLCR-23-691______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	_	Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
	-		

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
1-2	materials, drugs, medical		
1	writing, gifts or other		
	services		
13	Other financial or non-	None	
15	financial interests		

I have no conflict of interest

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: 26 October 2023 Your Name:_____GWO FUANG HO_____ Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):______TLCR-23-691______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	AUXI Therapeutics Taiho	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	Astrazeneca, Boeringher Ingelheim.	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony		
7	Support for attending meetings and/or travel	MSD.	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	Astrazeneca, MSD, Pfizer, Servier, Boeringher Ingelheim, Dr Reddy, Eisai, Adipolab, Amgen.	
		Aupolab, Angen.	
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
15	financial interests		

I report grants or contracts from AUXI Therapeutics and Taiho; payment or honoraria from AstraZeneca and Boehringer Ingelheim; support for attending meetings and/or travel from MSD; and participation on a Data Safety Monitoring Board or Advisory Board from Adipolab, Amgen, Astrazeneca, Boehringer Ingelheim, Dr Reddy, Eisai, MSD, Pfizer, Servier.

Please place an "X" next to the following statement to indicate your agreement:

X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 26 October 2023 Your Name:___Yong-Kek Pang

Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):_____ TLCR-23-691

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	<mark>Payment or honoraria for</mark>	AstraZeneca	Speaker
	lectures, presentations,	Pfizer	Speaker
	<mark>speakers bureaus,</mark>	GSK	Speaker
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	EuroDrug	European Respiratory Society Congress 2022
	meetings and/or travel	U	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	Novartis	Advisory Board
	Safety Monitoring Board or	Specialised Therapeutics	Advisory Board
	Advisory Board	MSD	Advisory Board
		Boehringer Ingelheim	Advisory Board
		Sanofi-Aventis	Advisory Board
		Orient Europharma	Advisory Board
		Pfizer	Advisory Board
		Amgen	Advisory Board
		Eurodrug Laboratories	Advisory Board
10	Leadership or fiduciary role	Lung Foundation of	Trustee
10	in other board, society,	Malaysia	
	committee or advocacy	walaysia	
	group, paid or unpaid	Malaysian Thoracic Society	Immediate Past President
	group, paid of difpaid		
11	Stack or stack antions	None	
11	Stock or stock options		
10			
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	MSD	Research funding
	<mark>financial interests</mark>		
		AstraZeneca	Research funding
		Sanofi	Research funding

I report payments as speaker from AstraZeneca, GSK, and Pfizer; support for attending the European Respiratory Society Congress 2022 from EuroDrug; participation on Advisory Boards for Amgen, Eurodrug Laboratories, Boehringer Ingelheim, MSD, Novartis, Orient Europharma, Pfizer, Sanofi-Aventis, and Specialised Therapeutics; research funding from AstraZeneca, MSD, and Sanofi; duty as trustee for Lung Foundation of Malaysia, and role as the Immediate Past President for the Malaysian Thoracic Society. Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

31 Oct 2023

for

Date: 26 October 2023 Your Name:____HARISSA HUSAINY HASBULLAH_____ Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):______TLCR-23-691

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have no conflict of interest

Please place an "X" next to the following statement to indicate your agreement:

"X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: 30 October 2023 Your Name:____LYE MUN THO_____ Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):_____TLCR-23-691_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
з	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events		Janssen, Astra Zeneca, Novartis, Pfizer, Roche, Boehringer Ingelheim, Fresenius Kabi
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel		Astra Zeneca, Roche, Boehringer Ingelheim, Fresenius Kabi
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non- financial interests	None	

I report payment or honoraria from AstraZeneca, Boehringer Ingelheim, Fresenius Kabi, Janssen, Novartis, Pfizer, and Roche; and support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, Fresenius Kabi, and Roche.

Please place an "X" next to the following statement to indicate your agreement:

__X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 26 October 2023 Your Name:_IBTISAM MUHAMAD NOR Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):______TLCR-23-691

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any	None	
2	entity (if not indicated in item		
	#1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Novartis Pfizer Eisei MSD	Received honorarium as speakers
		Amgen Astra Zeneca Mirati MSD Novartis	Received payment for Principle Investigator fee under CRM
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	Novartis Arcus Roche MSD Eisei ESMO	Received travel grant for educational meetings/Investigator meeting
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Board of Director Syarikat Hospital PUSRAWI Sdn. Bhd/ Syarikat MAIWP Healthcare Sdn Bhd	Receive monthly payment for BOD from 3 June 2021-2 June 2023
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I report speaker honoraria from Eisei, MSD, Novartis, and Pfizer; Principal Investigator fees under Clinical Research Malaysia from Amgen, AstraZeneca, Mirati, MSD, and Novartis; travel grant for educational meetings/investigator meeting from Arcus, Eisei, ESMO, MSD, Novartis, and Roche; and monthly payments as Board of Director for Syarikat Hospital PUSRAWI Sdn. Bhd/ Syarikat MAIWP Healthcare Sdn Bhd from June 2021 to June 2023. Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

	an Fatt Ho
Your Name	CANCER TO A STATE OF A
	ion of afatinib affect treatment outcomes of patients with EGFR-mutant metasta
non-small-cell lung cancer in real-w	vorld clinical practice?
Manuscript number (if known):	TLCR-23-691

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	เมษร สามาร์การ และ
3	Royalties or licenses	<u>V None</u>	
4	Consulting fees	None	

		T	
5	Payment or honoraria for lectures, presentations; speakers bureaus, manuscript writing or	None	CISA (
6	educational events Payment for expert testimony	<u>None</u>	
7	Support for attending meetings and/or trave!	None	MERCK
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	MSD
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock of stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	1997年1997日1993日1993日1993日1993日1993日1993日1993日
13	Other financial or non- financial interests	None	

I report payment or honoraria from EISAI; support for attending meetings and/or travel from Merck, and participation on a Data Safety Monitoring Board or Advisory Board for MSD.

Please place an "X" next to the following statement to indicate your agreement:

imes (certify that I have answered every question and bave not altered the wording of any of the questions on this

Date: 26 October 2023 Your Name: Muthukkumaran Thiagarajan Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):______TLCR-23-691

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	Yes	Received honoraria from Bohringer Ingelheim for a lecture on EGFR mutated NSCLC on 12/3/2023
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Yes	President of the Malaysian Oncological Society
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I report honoraria from Boehringer Ingelheim for a lecture in 2023 and is the current President of the Malaysian Oncological Society.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 26 October 2023

ATLINA BT SAMSUOIN

 Your Name:
 Attinue

 Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice?

 Manuscript number (if known):
 TLCR-23-691

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	a fill and a second s
-	lectures, presentations,		
125	speakers bureaus,		The second s
1.70-1	manuscript writing or		
-1.15	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	The should be a set of the second
1	meetings and/or travel		
11.2	meetings and/or traver		
5	A STATE OF A		TRUE BOUND TO A CAR CONTRACT OF A CAR STREET
		COLUMN TRACT	
1000	Contract of and provide a state		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	Men Add an
	Safety Monitoring Board or		The second s
	Advisory Board	Leave to a straight of	The new place of the second
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	RECEIPTION AND AND A COMPANY AND A
	Stock of stock options		
1400	The second second second		
12	Dessint of any immont	Nana	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
1 22	financial interests	the second s	
1 and	a set of a state of some of the	and the strength and the state of the	

I have no conflict of interest

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: 26 October 2023 Your Name:_AZZA OMAR_____ Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):______TLCR-23-691______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
0	testimony		
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
12	services	V. Neve	
13	Other financial or non- financial interests	XNone	
	inancial interests		

I have no conflict of interest

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. if you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entitles with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the Initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	None	
	medical writing, article processing charges, etc.) No time limit for this item. TLCR-23-691		
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	



5	Payment or honoraria for	None	
2	Payment or honorarla for lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

i have no conflict of interest

Please place an "X" next to the following statement to Indicate your agreement:

X I certify that I have answered every guestion and have not altered the wording of any of the questions on this form.





Date: 26 October 2023 Your Name: Sing Yang Soon

Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if

known):______TLCR-23-691

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or notfor-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Tin	ne frame: Since the initia	l planning of the work
1	All support for the	None	
	present manuscript		
	(e.g., funding, provision		
	<mark>of study materials,</mark>		
	medical writing, article		
	processing charges,		
	etc.)		

	No time limit for this		
	<mark>item.</mark>		
		Time frame: past	36 months
2	Grants or contracts	None	
	from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria	None	
	for lectures, presentations, speakers		
	bureaus, manuscript writing or educational		
6	Payment for expert testimony	None	
	restinony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued	None	
	<mark>or pending</mark>		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory		
	Board		
10	Leadership or fiduciary	None	
	role in other board, society, committee or		
	advocacy group, paid or		
11	Stock or stock options	None	

12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have no conflict of interest

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 26 October 2023 Your Name:____SIN NEE TAN_____ Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):_____TLCR-23-691_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
з	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have no conflict of interest

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date: 26 October 2023 Your Name:____Soon Hin How_____ Manuscript Title: Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small-cell lung cancer in real-world clinical practice? Manuscript number (if known):_____ TLCR-23-691

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present		Received funding from boehringer-ingelheim for medical writing
-	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	nine name. past	MSD, Janssen, AZ, Arcus, Merck, Novartis, pfizer,
-	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	lectures, presentations,		MSD, Janssen, AZ, Novartis, pfizer, Takeda
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	MSD
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data		MSD, Janssen, AZ, Novartis, pfizer, Takeda
9	Safety Monitoring Board or		NISD, Janssen, Az, Novartis, prizer, Takeua
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,		AZ, Novartis, pfizer, Takeda, BI
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

I report funding from Boehringer Ingelheim for medical writing; grants or contracts from Arcus, AstraZeneca, Janssen, Merck, MSD, Novartis, and Pfizer; payment or honoraria from AstraZeneca, Janssen, MSD, Novartis, Pfizer, and Takeda; support for attending meetings and/or travel from MSD; participation on a Data Safety Monitoring Board or Advisory Board from AstraZeneca, Janssen, MSD, Novartis, Pfizer, and Takeda, as well as receipt of equipment, materials, drugs, medical writing, gifts or other services from AstraZeneca, Boehringer Ingelheim,

Novartis, Pfizer, and Takeda.

Please place an "X" next to the following statement to indicate your agreement:

__X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.